ARA-290 guide & protocols

ARA-290, also called cibinetide, is the rarest thing on this site: a research peptide with genuine human research behind it, the kind where some people got the compound and some got a dummy injection and nobody knew which, run by a real company and aimed at a real diagnosis. It was studied in people with burning, painful nerve damage, and the work did something almost nothing else here has done. It tested three different amounts against placebo and reported which one worked. The answer was the middle one.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.

What it is

ARA-290 is eleven amino acids taken from erythropoietin, the hormone that tells your body to make red blood cells. Erythropoietin turns out to have a second job that has nothing to do with blood: it protects and repairs injured tissue, working through a completely separate receptor. That second receptor is what this fragment was designed to hit.

The reason it matters is what got left behind. Erythropoietin itself can't be used for tissue repair, because raising red blood cell counts thickens the blood and carries real cardiovascular risk. ARA-290 binds the repair receptor and not the blood-making one. It is, in other words, a deliberate attempt to keep the useful half of a hormone and discard the dangerous half, and unlike most such attempts on this site, somebody funded the human research to find out whether it worked.

What people use it for

Nerve pain, and specifically the small-fibre kind: burning feet, pins and needles, skin that hurts to touch, the pain that keeps you awake and doesn't show up on a standard nerve test. That's what the human research was in, and it's what most people come here for.

The relevant crossover for this audience is diabetes and prediabetes, where that kind of nerve damage is common and the available options are mostly medications that dull the pain rather than address the nerve. The animal work does extend to diabetic nerve damage, though the human research was in a different condition.

The third thread is general inflammation and tissue protection, which follows from the receptor rather than from any study in that use.

Formulations

ARA-290 ships as a lyophilized powder for subcutaneous injection. Across the vendors we track, two sizes dominate in an unusual way: 10 mg from about half of them, and 16 mg from most of the rest.

That 16 mg size is worth a second look, because it's a strange number that turns out not to be arbitrary. At the 4 mg daily amount the human research settled on, a 16 mg vial is exactly four days. Whether that's deliberate or coincidence, it tells you something about the scale this compound is actually used at.

Dosing protocols

This is one of a handful of pages on this site where the top row isn't convention. The human research tested three amounts against placebo and reported which one moved the measure it was designed to move.

See the ARA-290 research notes for the full research record.

All patterns above are subcutaneous injection.

More was not better, which is rare enough to say twice

Nearly every dosing conversation in this market assumes a straight line: if some helps, more helps more, and the only reason to run less is money. Here somebody actually checked. Eight milligrams a day was tested alongside four, and it did not outperform it.

So if 4 mg doesn't do anything for you after a month, doubling it is the one response the available evidence specifically doesn't support. That's an unusually clean piece of guidance for a compound on this site, and it's worth more than any amount of mechanism.

The cost, said plainly

This compound is dosed in milligrams, not micrograms, and that changes the economics completely. At the 4 mg daily amount the research supports, a 28-day course is 112 mg (4 mg times 28 days). That's seven 16 mg vials, or eleven and a bit 10 mg vials, for one month.

At the 1 to 2 mg the market actually runs, the same 28 days is 28 to 56 mg, which is a quarter to half the cost. That gap is almost certainly why the convention sits where it does, and it's worth being honest that the cheaper pattern is a budget decision rather than a finding. Price this against the full course before starting, not against a vial.

How much to reconstitute at once. The usual 28-day refrigerated window is irrelevant here at the higher amount, since a 16 mg vial is four days and a 10 mg vial is two and a half. Vials get used long before they can expire. Working example: 16 mg into 2 mL of bacteriostatic water gives 8,000 mcg per mL, so a 4 mg dose is 4,000 divided by 8,000, times 100, which is 50 units on a standard U-100 insulin syringe, and 2 mg is 25 units. See how much to reconstitute at once for the general math.

Cycling guidelines

A 28-day course is the shape, and unusually for this site that number comes from the research rather than from the market. What happens after 28 days was not studied, so anything said about repeating courses, spacing them, or running longer is invention.

The one useful observation from the research is that the effect being measured was nerve fibres regrowing, which is a slow structural change rather than a symptom being masked. That argues for judging a course at its end rather than expecting something in week one, and it argues against the idea that stopping immediately undoes it.

Signs a course is commonly stopped or reconsidered:

• Injection site reactions that don't settle, which matter more here because the injected volume is larger than most compounds on this site
• Headache or fatigue in the first week
• Any unexpected change in energy or exercise tolerance, which is worth mentioning to a clinician given what the parent hormone does
• A completed 28 days with no change, which is the point the research structure itself suggests reassessing rather than escalating

Stacking

Most commonly paired stack: ARA-290 with BPC-157.

Rationale: both are reached for on nerve and tissue complaints, and the argument is that they work through unrelated mechanisms. It's a reasonable pairing and there's no combination data for it, as usual.

Protocol as run: both once daily, on their own schedules, as separate injections. ARA-290's 28-day course and BPC-157's longer conventional runs don't line up neatly, so people generally run each on its own pattern rather than forcing a shared one.

Lighter stacks: where the underlying problem is blood sugar, the GLP-1 compounds come up, on the reasoning that addressing the cause alongside the nerve damage makes more sense than treating the nerve alone. That's sound thinking rather than a studied combination.

Combinations to approach carefully: nothing specific is flagged. The one worth thinking about is anything else affecting red blood cell production, on the general principle that this compound was built from a hormone that does exactly that, even though the whole design intent was to leave that effect behind.

Expected results timeline

First weeks: not much, and that's expected. The change being produced is nerve fibres regrowing, which is slow by nature. Where pain relief was reported it emerged over the course rather than in the first days.

At 28 days: this is where the research measured, and where the nerve fibre density change and the reported reduction in pain both showed up. It's the honest point at which to judge a course.

Beyond that: unknown. The human research ran 28 days and stopped, so how long the effect lasts, whether it continues, and what repeated courses do are all open.

What to expect realistically: the evidence here is better than almost anything else on this site and it is still small. Sixty-four people, one condition, one month, at two centres. The effect it found was real and measured on a scan rather than reported on a questionnaire, which matters. But it was in painful nerve damage from sarcoidosis specifically, and whether the same thing happens in nerve damage from diabetes or from anything else has not been shown in people.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe. Note the volumes are larger here than elsewhere on this site: 50 units at the researched amount is half a syringe, not the few units most compounds need.
4. A subcutaneous site is chosen, commonly the abdomen or thigh, with sites rotated daily. Rotation matters more than usual because of that larger volume.
5. The skin is pinched and the injection given at roughly a 45-degree angle.
6. Timing is unconstrained: no meal or sleep dependency, so the dose goes wherever it fits the day.
7. The date is commonly logged, since the protocol is a defined 28 days and the end of it is a decision point rather than a drift.

Side effects and safety

Common: injection site reactions, which are the most reported and are consistent with the larger injected volume. Headache and fatigue come up occasionally.

Less common: nothing consistently reported. The human research specifically noted no significant safety problems in any of the three amounts tested, including the 8 mg group.

What we know, unusually: that safety observation comes from research in actual patients with a dummy-injection comparison group, which is a considerably better basis than community reports. It covers 28 days.

What we don't know: anything beyond a month. Whether the intended separation from red blood cell production holds perfectly over longer use, in people, is not established by 28 days of data, even though it's the entire design premise and nothing in the research contradicted it. Use in nerve damage from causes other than the one studied is untested in people.

Contraindications: pregnancy, breastfeeding and use in minors have no data. Anyone with a blood disorder, a history of clotting, or a condition affecting red blood cell counts should treat this as a conversation with a clinician rather than a purchase, given the hormone it derives from.

Drug interactions: none established. Anything affecting red blood cell production or clotting is the category worth being cautious about on principle.

ARA-290 vs. BPC-157

BPC-157 is what most people reach for when a nerve or tissue problem sends them to this market, so it's the honest comparison even though the two are not really alike.

Choose ARA-290 if: the problem is specifically small-fibre nerve pain, and you want the compound with real human research and a known effective amount, and you can afford to run it at that amount.

Choose BPC-157 if: the problem is tissue rather than nerve, or the cost of a proper ARA-290 course rules it out.

See the BPC-157 guide and protocols for its own dosing.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C and protect from light. Kept frozen, the unreconstituted powder is commonly described as stable considerably longer, which matters here because a full course means buying several vials at once. Take lot-specific stability from the vendor's certificate of analysis.

Reconstituted solution: refrigerate and use within about 28 days. At the researched amount this window never binds, since a vial lasts days rather than weeks. At the lower market amounts it can, so mix what a fortnight actually uses rather than the whole vial.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or the reconstituted liquid
• Powder that has clumped or gone sticky, which usually means moisture reached it

FAQ

How much did the research actually use? 4 mg once daily for 28 days. It also tested 1 mg and 8 mg; 4 mg was the amount that met the measure, and 8 mg was not better.

Why does the market run 1 to 2 mg then? Cost. A proper 28-day course at 4 mg is 112 mg of material. Nothing establishes the lower amount as equally effective.

Will it raise my red blood cell count? The entire design intent was to keep the repair effect and drop that one, and the human research found no significant safety problems over 28 days. Longer than that hasn't been examined.

Does it work for diabetic neuropathy? The animal work extends there. The human research was in nerve damage from sarcoidosis, so the crossover is reasonable but not demonstrated in people.

How long before I know? Judge it at 28 days. What's being changed is nerve fibres regrowing, which is slow, and the research measured at a month.

Should I go higher if 4 mg does nothing? That's the one move the evidence specifically doesn't support, since 8 mg was tested and wasn't better.

Why are the vials 16 mg? At 4 mg daily that's exactly four days. The odd size makes sense once you know the scale it's used at.

How is it stored? Refrigerated and out of the light, frozen for the vials you aren't using yet, since a course means buying several.

Bottom line

Key dosing takeaways:

• 4 mg once daily for 28 days is what the human research supports, and it's the rare figure on this site that comes from a study rather than from the market
• 8 mg was tested and was not better, so escalating is the one response the evidence argues against
• The 1 to 2 mg the market runs is a cost decision, not a finding

Best practices:

• Pricing the full 112 mg course before starting, since this is dosed in milligrams and the arithmetic surprises people
• Running the defined 28 days and judging at the end, rather than expecting something in the first week
• Rotating injection sites deliberately, since the injected volume is much larger than the compounds either side of it on this site

Works best for people who:

• Have small-fibre nerve pain specifically, rather than a general tissue complaint
• Want the compound with the best human evidence on the site and will run it at the amount that evidence supports
• Can absorb what a real course costs, or would rather not start than run a quarter dose and learn nothing

ARA-290 is sold for research, and the human work behind it is 64 people, one condition, one month. You already know that. You're an adult making an informed call about your own body, and that's yours to make.